NCT05757856View on ClinicalTrials.gov

A Study to Investigate Safety and Tolerability of NDX-3315 and NDX-3324 in Healthy Participants and Patients With Eosinophilic Esophagitis

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 20, 2023

Primary Completion Date

May 22, 2025

Study Completion Date

May 22, 2025

Conditions
Eosinophilic Esophagitis
Interventions
DRUG

NDX-3315 and NDX-3324

Oral solution

Trial Locations (3)

19104

University of Pennsylvania, Philadelphia

60611

Northwestern Univerisity, Chicago

84132

University of Utah, Salt Lake City

Sponsors
All Listed Sponsors
lead

NexEos Diagnostics, Inc.

INDUSTRY